Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a promising biotech company that utilizes AI technology to minimize downstream development risks and optimize their precision antibodies. The company has shown promising preclinical results and recently transitioned to clinical-stage, with their first drug candidate, IBIO-600, entering human trials. The company's strong pipeline and potential for future revenue have resulted in a 12-month price target of $5 per share. However, as a development stage company, there are inherent risks involved, including the need to raise additional funds and potential intellectual property infringement.

Bears say

iBio is a preclinical biotech company with a negative outlook due to potential competition, challenges with intellectual property protection, and the possibility of future dilution for stockholders. Despite their current orphan drug status and plans for niche market sales, the company may face difficulties in securing external financing and navigating the complex clinical and regulatory landscape.

iBio (IBIO) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 5 analysts, iBio (IBIO) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.